Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VICTOR trial of venetoclax versus standard intensive chemotherapy in NPM1-mutated acute myeloid leukaemia
ISRCTN15567173Phase 2Active, not recruiting
- Sponsor
- University of Birmingham
- Start
- Mar 2021
- Modality
- Small Molecules, Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
01
Overview
Phase 2, randomised, open-label trial of venetoclax, cytarabine, daunorubicin and gemtuzumab ozogamicin in acute myeloid leukemia (AML) (2 arms), sponsored by University of Birmingham. Primary endpoint: Molecular event-free survival. Started Mar 2021; status: active, not recruiting.
02
Drugs
venetoclaxcytarabinedaunorubicingemtuzumab ozogamicin
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on ISRCTN15567173.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN15567173.